Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Pfizer Inc.

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial

February 03, 2025

From Pfizer Inc.

Via Business Wire

Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium

January 28, 2025

From Pfizer Inc.

Via Business Wire

Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

January 25, 2025

From Pfizer Inc.

Via Business Wire

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

January 10, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

January 06, 2025

From Pfizer Inc.

Via Business Wire

U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

December 20, 2024

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts

December 19, 2024

From Pfizer Inc.

Via Business Wire

Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance

December 17, 2024

From Pfizer Inc.

Via Business Wire

Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer

December 12, 2024

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance

December 10, 2024

From Pfizer Inc.

Via Business Wire

Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS

December 05, 2024

From Pfizer Inc.

Via Business Wire

Pfizer Announces New Chief Scientific Officer and President, Research & Development

November 20, 2024

From Pfizer Inc.

Via Business Wire

European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors

November 20, 2024

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

November 14, 2024

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

November 04, 2024

From Pfizer Inc.

Via Business Wire

Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance

October 29, 2024

From Pfizer Inc.

Via Business Wire

Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

October 23, 2024

From Pfizer Inc.

Via Business Wire

U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease

October 22, 2024

From Pfizer Inc.

Via Business Wire

Tim Buckley Elected to Pfizer’s Board of Directors

October 15, 2024

From Pfizer Inc.

Via Business Wire

U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

October 11, 2024

From Pfizer Inc.

Via Business Wire

Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial

October 10, 2024

From Pfizer Inc.

Via Business Wire

Pfizer Declares Fourth-Quarter 2024 Dividend

October 09, 2024

From Pfizer Inc.

Via Business Wire

Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024

October 08, 2024

From Pfizer Inc.

Via Business Wire

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

September 25, 2024

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

September 20, 2024

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts

September 17, 2024

From Pfizer Inc.

Via Business Wire

Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia

September 14, 2024

From Pfizer Inc.

Via Business Wire

Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

September 14, 2024

From Pfizer Inc.

Via Business Wire

Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024

September 11, 2024

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

August 28, 2024

From Pfizer Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.